KRAS-mutant cancers: Potential target could overcome treatment resistance Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor growth and resistance to KRAS inhibitors in patients with KRAS-mutant cancers.
https://medicalxpress.com/news..../2025-12-kras-mutant